LUTZ | ABEL advised Hemovent on exit transaction to MicroPort Surgical
Munich, Germany — MicroPort Scientific Corporation, through its subsidiary MicroPort Surgical B.V., has acquired 100% of the shares in Hemovent GmbH for a purchase price of up to EUR 123 million.
Founded in 2013 in Aachen, Germany, Hemovent is a medical device company specializing in the development of breakthrough extracorporeal life support (ECLS) systems. Hemovent’s flagship MOBYBOX® system is the first fully integrated ECLS system that controls both perfusion and gas exchange in a single device, setting a new standard for ECMO devices in terms of mobility and ease of use.
MicroPort® has established itself in the critical care field through its subsidiary MicroPort® Surgery, which is committed to providing patients with comprehensive medical solutions for cardiac surgery, emergency medicine and critical care. The acquisition of Hemovent will further advance MicroPort®’s emergency and critical care strategy by combining cardiopulmonary bypass (CPB) with research and development, manufacturing and marketing of ECMO products.
Legal advisor to the shareholders of Hemovent GmbH: LUTZ | ABEL Rechtsanwalts PartG mbB
The advisory team around Dr. Bernhard Noreisch (photo), Partner (lead, Munich) included Dr. Cornelius Renner (IP, Berlin), Frank Hahn (M&A, Hamburg) and Jan-Phillip Kunz (VC/M&A, Munich).
Legal advisors MicroPort Surgical B.V.: Freshfields Bruckhaus Deringer (Frankfurt a. Main / Hamburg)
M&A Advisor: William Blair, London
About LUTZ | ABEL
With around 85 lawyers and offices in Munich, Hamburg, Stuttgart and Berlin, the commercial law firm LUTZ | ABEL provides advice on all aspects of commercial law.